Click any tag below to further narrow down your results
Links
AI has made generating hypotheses and running simulations cheap, but the actual experimental verification remains slow and expensive — a gap that will determine how much AI truly accelerates scientific discovery. The bottleneck isn't computing power; it's the physical work of building things, measuring them, and getting reproducible results.
- In formal math and software, verification is nearly free once problems are machine-checkable (Lean proofs, AlphaEvolve), so the limiting factor becomes compute. But most science requires physical experiments that can't be sped up by better algorithms.
- Amdahl's law shows the hard limit: if 80% of discovery time is lab work, infinitely fast hypothesis generation only delivers 1.25× speedup. Better models widen the verification gap rather than close it.
- Cheap compute creates "orphaned hypotheses" — promising candidates generated by grad students and small teams that go untested because experimental capacity is concentrated in a few rich institutions and countries. Accessible, affordable lab tools could democratize who can run the full loop of science.
- Surrogates like AlphaFold work only when built on high-quality experimental data and validated with real measurements. A country or company that scales compute without matching lab infrastructure and data capacity will have fast models that are confidently wrong.
Daron Acemoglu argues that while AI's potential for drug discovery is often used to justify massive investments, the evidence shows AI has delivered little so far—and redirecting some of that money toward proven public health interventions would do far more to improve American life expectancy.
- AI has produced minimal gains in actual drug discovery despite significant effort. A recent paper found that while AlphaFold predicted protein structures, there's "no evidence so far that more applied, early-stage drug development is targeting these proteins."
- The US has the lowest life expectancy among wealthy nations (about 5 years behind Switzerland, Sweden, Japan), mostly from preventable deaths before age 70 due to chronic disease, overdoses, and poor public health—not lack of new drugs.
- The US spends far more on healthcare than peer countries but too little on public health (preventive care, nutrition, immunization, primary care access), suggesting reallocating AI investment toward these proven interventions would yield better health outcomes.
This post lists nine key quotes from a San Francisco talk by Demis Hassabis and Sebastian Mallaby covering everything from OpenAI’s 50% bankruptcy risk to the need for new “AlphaFold” moments in drug discovery. They debate AGI probabilities, frontier cyber defense access, global AI optimism, and the economic and philosophical challenges of a post-scarcity future.
- Mallaby puts a 50% chance OpenAI goes bankrupt within 18 months
- Hassabis says six more AlphaFold-level breakthroughs are needed to cut drug-delivery timelines from 10 years to months
- Hassabis calls the idea that p(doom) is zero "crazy," acknowledging real existential risk from AI
- Hassabis argues economists, social scientists, and philosophers must join scientists in shaping decisions about how AI's value gets shared